<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04174092</url>
  </required_header>
  <id_info>
    <org_study_id>LOCAL 2019/CGV/01</org_study_id>
    <secondary_id>2019.A01715-52</secondary_id>
    <nct_id>NCT04174092</nct_id>
  </id_info>
  <brief_title>Catastrophism in Chronic Inflammatory Rheumatism</brief_title>
  <acronym>CRIC</acronym>
  <official_title>Catastrophism in Chronic Inflammatory Rheumatism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Catastrophic is defined as a negative cognitive and emotional response based on inadequate&#xD;
      pain expression. It has three components: rumination, amplification and vulnerability. The&#xD;
      assessment of catastrophism is carried out using a validated questionnaire called the &quot;Pain&#xD;
      Catatrophizing Scale&quot; (PCS).&#xD;
&#xD;
      Recent studies highlight the significant impact of catastrophism in neuromuscular and&#xD;
      mechanical rheumatic diseases such as gonarthrosis gonalgia and low back pain. In these&#xD;
      diseases, it has been shown that catastrophism has a negative impact both on the experience&#xD;
      of pain and on the response to different types of treatments (medical and surgical). Several&#xD;
      studies have implemented multidisciplinary management and in particular cognitive-behavioural&#xD;
      therapy with an improvement in the pain experience in patients who are catastrophic.&#xD;
&#xD;
      In chronic inflammatory rheumatic diseases such as rheumatoid arthritis, spondyloarthritis&#xD;
      and psoriatic arthritis, the prevalence and impact of catastrophism is still poorly&#xD;
      understood.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 27, 2019</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>catastrophic assessment</measure>
    <time_frame>Day 0</time_frame>
    <description>Pain Catastrophism Scale (0= no catastrophism, 52 = maximum catastrophism)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>catastrophic assessment</measure>
    <time_frame>at 3 months</time_frame>
    <description>Pain Catastrophism Scale (0= no catastrophism, 52 = maximum catastrophism)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>catastrophic assessment</measure>
    <time_frame>at 6 months</time_frame>
    <description>Pain Catastrophism Scale (0= no catastrophism, 52 = maximum catastrophism)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>catastrophic assessment</measure>
    <time_frame>at 12 months</time_frame>
    <description>Pain Catastrophism Scale (0= no catastrophism, 52 = maximum catastrophism)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">533</enrollment>
  <condition>Chronic Inflammatory Rheumatism</condition>
  <arm_group>
    <arm_group_label>rheumatoid arthritis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Filling in several self-questionnaires: on function (HAQ), pain EVA, quality of life (SF12, EQ5D), anxiety score (GAD-7), insomnia score (ISI), catastrophic score (PCS), coping score (coping ability, CSQ), compliance scores (CQR, Health Insurance Compliance Assessment Questionnaire) and fibromyalgia diagnostic score (FiRST), activity of rheumatic disease (RAID, RAPID-3) Patients will be seen at 3, 6 and 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>spondyloarthritis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Filling in several self-questionnaires: on function (HAQ), pain EVA, quality of life (SF12, EQ5D), anxiety score (GAD-7), insomnia score (ISI), catastrophic score (PCS), coping score (coping ability, CSQ), compliance scores (CQR, Health Insurance Compliance Assessment Questionnaire) and fibromyalgia diagnostic score (FiRST), activity of rheumatic disease (BASDAI, BASFI).&#xD;
Patients will be seen at 3, 6 and 12 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Psoriatic arthritis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Filling in several self-questionnaires: on function (HAQ), pain EVA, quality of life (SF12, EQ5D), anxiety score (GAD-7), insomnia score (ISI), catastrophic score (PCS), coping score (coping ability, CSQ), compliance scores (CQR, Health Insurance Compliance Assessment Questionnaire) and fibromyalgia diagnostic score (FiRST), activity of rheumatic disease (BASDAI, BASFI).&#xD;
Patients will be seen at 3, 6 and 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>completing self-questionnaires</intervention_name>
    <description>completing self-questionnaires on quality of life, anxiety, insomnia, activity of rheumatic disease and catastrophism</description>
    <arm_group_label>Psoriatic arthritis</arm_group_label>
    <arm_group_label>rheumatoid arthritis</arm_group_label>
    <arm_group_label>spondyloarthritis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Major patients, hospital follow-up, with RA according to ACR 2010 criteria, or&#xD;
             spondyloarthritis according to ASAS 2009 criteria or according to AMOR or psoriatic&#xD;
             arthritis according to Caspar 2006 criteria.&#xD;
&#xD;
          -  Patient who has given free and informed consent.&#xD;
&#xD;
          -  Patient who has signed the consent form.&#xD;
&#xD;
          -  Patient affiliated or benefiting from a health insurance plan.&#xD;
&#xD;
          -  Adult patient (≥18 years old).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient under the protection of justice, under guardianship or curatorship.&#xD;
&#xD;
          -  Patient unable to express consent.&#xD;
&#xD;
          -  Patient for whom it is impossible to provide informed information.&#xD;
&#xD;
          -  Poor command and understanding of the French language making it impossible to complete&#xD;
             self-questionnaires&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anissa MEGZARI</last_name>
    <role>Study Director</role>
    <affiliation>Centre Hospitalier Universitaire de Nīmes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34 295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nîmes</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 19, 2019</study_first_submitted>
  <study_first_submitted_qc>November 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2019</study_first_posted>
  <last_update_submitted>March 24, 2021</last_update_submitted>
  <last_update_submitted_qc>March 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Catastrophism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rheumatic Fever</mesh_term>
    <mesh_term>Rheumatic Diseases</mesh_term>
    <mesh_term>Collagen Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

